Sorrento Therapeutics Inc., of San Diego, is selling $120.5 million of unsecured convertible notes in a private placement to accredited investors. Read More
Cyxone AB, of Stockholm, concluded the first phase of a pilot study investigating the effect of cyclotides against inflammatory bowel disease (IBD) in an acute animal model of the condition. Read More
PERTH, Australia – Pharmaceutical companies wanting to submit new drug applications in Australia now have additional pathways thanks to new drug legislation aimed at speeding access to therapies. Read More
Caelum Biosciences Inc. enhanced its cachet with an analysis of data from the phase Ib trial of its chimeric fibril-reactive monoclonal antibody (MAb), CAEL-101 (11-1F4), that showed a correlation between sustained decrease in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and improvement in global longitudinal strain (GLS) in individuals with cardiac amyloid light chain (AL) amyloidosis. Read More
Last year, after Merck & Co. Inc. "put this stake in the ground" to establish the importance of the retinoic acid-induced gene I (RIG-I) pathway by acquiring Rigontec GmbH, other pharma firms sat up and took notice, said Kristin Bedard, chief scientific officer of Kineta Inc. Read More
U.S. Worldmeds LLC's Lucemyra (lofexidine) moved another step closer to the U.S. market Tuesday with an 11-1 advisory committee vote recommending FDA approval of the drug to mitigate symptoms of opioid withdrawal. Read More
